Article

FDA Issues CRL to Mylan for Advair Generic

Author(s):

The specifics of the "minor deficiencies" cited by the FDA will be relayed on June 27, 2018, upon the official issuance of the CRL.

The US Food and Drug Administration (FDA) has sent Mylan a Complete Response Letter (CRL) for its abbreviated new drug application (ANDA) for its generic fluticasone and salmeterol oral inhaler.

The CRL identified “minor deficiencies,” according to Mylan, and as the generic inhaler was granted priority designation, an approval based on the response to the FDA could be granted in a shorter time frame than the standard 90-day time period.

The specifics of the aforementioned minor deficiencies will be relayed on June 27, 2018, upon the official issuance of the CRL.

“Upon receipt of the official Complete Response Letter, we will determine what, if any, impact that it could have on our full year 2018 outlook,” the company declared in a statement.

This is the second CRL received for the inhaler, a generic form of GlaxoSmithKline’s Advair. It was originally submitted to the FDA in December 2015, and Mylan was sent a CRL in March 2017, which did not detail why the therapy was not approved. The inhaler was resubmitted for a second ANDA shortly after.

Advair Diskus, an inhaler glucocorticoid and long-acting beta-2 agonist for asthma patients of a similar age, lost its US patent protection in 2010.

Related Videos
How to Manage Aspirin-Exacerbated Respiratory Disease
Safety Data on Dupilumab, Ensifentrine for COPD, with MeiLan Han, MD
MeiLan Han, MD: Discussing Updates on Dupilumab, Ensifentrine in 2025 GOLD Report
Physician, Patient, and Partner Perspectives on AERD with Mitchell Grayson, MD, Rhonda Nelson, and Wayne Nelson
Monica Kraft, MD: Discussing Phase 3b Findings on Albuterol/Budesonide for Asthma
How Artificial Intelligence is Being Used in Lung Imaging, with Rachel Eddy, PhD
Developing Risk Assessment Tools for Viruses in School
Using Microbiomes to Diagnose Ventilator-Associated Pneumonia
What Do Patients Need to Learn About their Hypersensitivity Pneumonitis?
© 2024 MJH Life Sciences

All rights reserved.